For many years, one of the world's top scientists, synthetic organic chemist James Tour, has led a team developing next-generation technology to target and kill cancer cells with virtually no side effects.

Tour, a professor of chemistry at Rice University in Houston, is using nanomachines – the marvelous "motorized" organic molecules created in a lab that won three chemists a Nobel Prize in 2016 – to target cancerous cells. After affixing themselves to the diseased cell, Tour's novel nanomachines – equipped with a rotor and a stator – are activated by ultraviolet light to drill through the cell membranes at a speed of up to 3 million times per second. The cancer cells then can be killed either by injecting chemical agents to destroy them, or by repeatedly piercing the cell to blast open tumorous membranes until the cell dies by necrosis.

The use of that technology to treat cancer and other diseases is closer to reality now, with the launch of an Israeli company called Nanorobotics.

Therapies, though perhaps six years from the market, are now in the pre-clinical trial stage for treatment of glioblastoma, non-muscle invasive bladder cancer, and squamous and basal cell carcinoma.

WND spoke with the company's chief technology officer, Shlomo Nedvetzki, at the annual COSM conference in Bellevue, Washington, hosted by the Discovery Institute.

Born in Israel, Nedvetzki is the son of immigrants from Eastern Europe. He has a Ph.D. in immunology from Hebrew University Medical School and a post-doctoral degree from Imperial College London.